Bradford D. Dahms's most recent trade in Jade Biosciences Inc was a trade of 526,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Jade Biosciences Inc | Bradford D. Dahms | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2025 | 526,000 | 526,000 | - | - | Stock Option (Right to Buy) | |
| Theseus Pharmaceuticals Inc | Bradford D. Dahms | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 17,500 | 17,500 | - | - | Restricted Stock Units | |
| Theseus Pharmaceuticals Inc | Bradford D. Dahms | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 105,000 | 105,000 | - | - | Stock Option (right to buy) | |
| Theseus Pharmaceuticals Inc | Bradford D. Dahms | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.66 per share. | 30 Nov 2022 | 1,502 | 6,142 | - | 6.7 | 10,000 | Common Stock |
| Theseus Pharmaceuticals Inc | Bradford D. Dahms | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Theseus Pharmaceuticals Inc | Bradford D. Dahms | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 10.15 per share. | 21 Dec 2021 | 1,970 | 1,970 | - | 10.2 | 20,000 | Common Stock |
| Selecta Biosciences Inc | Bradford D. Dahms | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 230,000 | 230,000 | - | - | Employee Stock Option (right to buy) | |
| Selecta Biosciences Inc | Bradford D. Dahms | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 38,000 | 38,000 (0%) | 0% | 0 | Common Stock |